Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other central nervous system disorders. and peripheral in the United States. The company is headquartered in Redmond, Washington.